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Background: Sentinel lymph node (SLN) biopsy allows surgeons to identify patients with
subclinical nodal involvement who may benefit from lymphadenectomy and, possibly, adjuvant
therapy. Several factors have been variably, and sometimes discordantly, reported to have predictive
value for SLN metastasis to best select which patients require SLN biopsy.
Methods: We reviewed 419 patients who underwent SLN biopsy for melanoma from a prospec-
tively collected melanoma database. To derive a probabilistic model for the occurrence of a positive
SLN, a multivariate logistic model was fit by using a stepwise variable selection method. The
accuracy of each model was evaluated by using receiver operator characteristic curves.
Results: On univariate analysis, the number of mitoses per square millimeter, increasing Breslow
depth, decreasing age, ulceration, and melanoma on the trunk showed a significant relationship to
a positive SLN. Multivariate analysis revealed that once age, mitotic rate, and Breslow thickness
were included, no other factor, including ulceration, was significantly associated with a positive
SLN. The data suggest that younger patients with tumors 1 mm may still have a substantial risk
for a positive SLN, especially if the mitotic rate is high.
Conclusions: In addition to Breslow depth, mitoses per square millimeter and younger age were
factors identified as independent predictors of a positive SLN. This model may identify patients with
thin melanoma at sufficient risk for metastases to justify SLN biopsy.
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One of the most significant advances in the manage-
ment of primary cutaneous melanoma has been the con-
cept of lymphatic mapping and sentinel lymph node
(SLN) biopsy. Since the initial landmark publication by
Morton et al.1 that applied the concept to melanoma only
a decade ago, lymphatic mapping and SLN biopsy have
evolved through refinement, clinical experience, and
clinical trials to become an invaluable technique for
identifying patients who harbor subclinical lymph node
metastasis, with minimal morbidity.1–7 By documenting
those with subclinical nodal involvement, surgeons are
now able to identify patients who may benefit from
lymphadenectomy and possibly adjuvant therapy while
sparing patients with negative SLN biopsy results from
the morbidity associated with these treatments. Further-
more, the single most important factor to date that de-
termines overall prognosis and survival for stage I and II
melanoma is the SLN status.1–7
SLN biopsy is widely accepted as a means of staging
the lymph nodes for melanoma and is practiced as stan-
dard care at virtually all major melanoma centers.6
Breslow thickness (measured in millimeters) is the only
reproducible factor predictive of SLN status in all stud-
ies.1–3,7–23 Several other factors have been variably and
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sometimes discordantly reported to have predictive value
for SLN metastasis, including Clark level, ulceration,
mitotic rate, microsatellitosis, angiolymphatic invasion,
vertical growth phase, number of nodal basins, primary
tumor location, and patient age.1–3,7–23 Several plausible
explanations could account for the disparate and some-
times conflicting predictive models that have been of-
fered to date. Foremost among them is the use of differ-
ent sets of predictors. Few studies involve all known
predictive factors, so no two models start with identical
sets of possible predictors. Less readily recognized—but
no less significant—is the fact that many different com-
binations of predictors can yield a model that has a
strong correlation with SLN status. Unless different
models are compared directly by using the same data set,
there is no way to determine how well a particular model
performs.
For this study, we reviewed a prospectively collected
comprehensive melanoma database and identified 429
consecutive patients who underwent SLN biopsy at a
single institution. The primary objective was to assess
the factors that most strongly influence the probability of
finding a positive SLN in patients with cutaneous mela-
noma. Secondary objectives included the following: to
understand the effects of and interactions between mul-
tiple factors in a probabilistic model of SLN metastasis,
to explore the degree to which any combination of avail-
able factors can fully predict the status of the SLNs, and
to estimate whether any patient subgroups currently not
routinely considered for SLN biopsy are in fact at a
high-enough risk of having nodal metastasis to justify
prospectively evaluating extended indications for SLN
biopsy.
METHODS
Approval of the study was granted by the University
of Michigan Institutional Review Board for Medicine.
Our prospective melanoma database was queried for
patients entered from January 1996 to August 1999 to
identify consecutive patients who underwent lymphatic
mapping and SLN biopsy. Patients were grouped by the
presence or absence of metastatic melanoma in at least
one SLN; thus, patients with one or more positive nodes
were considered as having a positive SLN biopsy.
Histological Features
The histological features analyzed were Breslow
thickness (measured in millimeters), deep margin status
(to identify incisional or shave biopsies), growth phase
(vertical vs. radial), and the number of mitoses per
square millimeter (1 mm2 is approximately equal to four
to five high-power [40] microscope fields, counted
beginning in the fields with the most mitoses), as well as
the presence or absence of the following: angiolymphatic
invasion, regression, microsatellitosis, ulceration, neuro-
tropism, and periadnexal extension. The site of the pri-
mary melanoma was also evaluated and categorized into
one of four anatomical locations: head and neck, trunk,
upper extremity, or lower extremity. Patients with a
melanoma located on any mucous membrane or on the
genitalia were excluded from the analysis. In addition,
the effects of age and sex were also considered. All
primary lesions were evaluated prospectively and with-
out knowledge of the subsequent status of the SLN
biopsy by a dermatopathologist with expertise in mela-
noma by using a comprehensive 14-point melanoma
profile generated for every primary lesion.
Two more variables were created from the existing
database to compare this analysis with one previously
performed and reported by Mraz-Gernhard et al.8 The
first was a high mitotic rate, defined by those authors as
more than five mitoses per square millimeter. The other
was the total number of high-risk factors, which they
defined as the number of the following factors present in
a given lesion: ulceration, high mitotic rate, microsatel-
litosis, angiolymphatic spread, vertical growth phase,
and regression (but not Breslow depth).
SLN Biopsy Technique
In general, patients with lesions 1.0 mm in Breslow
depth or 1.0 mm with at least one adverse histopatho-
logic feature (ulceration, positive deep margin, or signif-
icant regression) were considered for lymphatic mapping
and SLN biopsy. Clark level was not used as an indica-
tion for SLN biopsy of thin lesions. Patients with a
previous wide excision (1-cm margin) and those with
significant comorbidities were not considered good can-
didates for lymphatic mapping and SLN biopsy and were
evaluated for biopsy on an individualized basis but were
not arbitrarily excluded. All patients underwent same-
day preoperative lymphoscintigraphy in which 99mTc
sulfur colloid (CIS-US Inc., Bedford, MA) was injected
intradermally around the primary lesion or biopsy site 2
to 4 hours before surgery to identify lymphatic basins
and in-transit nodes at risk. Patients in whom the lym-
phoscintigram showed no obvious transit of radionuclide
to any nodal basin were evaluated during surgery, and an
attempt was made to locate the SLN by using a handheld
gamma probe and blue dye. Patients in whom there was
transit to multiple basins were approached selectively,
and as many as four but generally no more than two
basins were subjected to biopsy. After induction of sat-
isfactory anesthesia (usually general inhaled anesthesia
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administered by laryngeal mask or endotracheal tube),
isosulfan blue dye (Lymphazurin 1%; Hirsch Industries
Inc., Richmond, VA) was injected intradermally around
the primary lesion or narrow excision biopsy site, and the
area was massaged to promote lymphatic flow. After
approximately 5 to 10 minutes, a handheld gamma probe
(Navigator GPS; US Surgical, Cincinnati, OH) was used
to identify “hot” spots over the SLNs. A small incision
was made directly overlying the hot spots and carried
down through the skin and subcutaneous tissue into the
node-bearing fat. Any blue-stained, hot (defined as the
hottest node and any other nodes within 10% of the
counts per minute of the hottest node), or palpably ab-
normal nodes were considered SLNs. Once identified,
the SLNs were excised and sent for careful histopatho-
logic analysis. Definitive wide excision of the primary
cutaneous melanoma was then performed. SLNs were
evaluated by one of two dermatopathologists with expe-
rience and expertise in melanoma and SLN evaluation.
SLNs were serially sectioned and stained with hematox-
ylin and eosin (H&E). H&E-negative nodes were further
stained with a battery of immunohistochemistry stains,
most often consisting of S-100, Melan-A, and HMB-45,
as previously described.24 Reverse transcriptase-poly-
merase chain reaction was not used to evaluate any
SLNs.
Statistical Analysis
The event of interest was defined as the presence of
one or more H&E- or immunohistochemistry-positive
SLNs discovered during any SLN biopsy on a particular
patient. To determine the association between each clin-
ical or pathologic factor and the event of interest, a
logistic regression model was fit with each factor by
itself and each factor adjusted for the age and sex of the
patient. By using the parameter estimates from these
models, the P value from the Wald 2 test for the
significance of the parameter, the odds ratio, and a 95%
Wald-based confidence interval for the odds ratio were
reported. We do not undertake any formal adjustment of
P values, even though multiple tests were performed.
Because of the exploratory nature of the search for vari-
ables that were associated with SLN positivity, the reader
should be cautious not to overinterpret the importance of
variables that have marginally significant associations.
To derive a probabilistic model for the occurrence of
one or more positive SLNs, a multivariate logistic model
was fit by using a stepwise variable selection method.
Factors were entered into the model if they were inde-
pendently significant at the .10 level but were dropped if
they were not significant at the .05 level when adjusted
for variables already in the model. To compare the ef-
fects when adjusted for age and sex and to allow com-
parison with other published data, a second multivariate
model was fit in the same stepwise fashion, only this
time age and sex were forced into one model. Finally, a
model containing all two-way interactions between sig-
nificant variables was considered. The analysis was per-
formed with SAS PROC LOGISTIC (version 6.12; SAS
Institute, Cary, NC), which discards an entire record if it
contains a missing value for either the outcome variable
or one of the variables in the model.
The accuracy of each model was evaluated by using
receiver operator characteristic (ROC) curves. The ROC
is a plot of (1  specificity) versus sensitivity and is
frequently used to evaluate diagnostic procedures. For an
ideal predictive test, both the sensitivity and specificity
should be high, as occurs when the ROC curve is shaped
like an inverted L, with its corner close to the top left
corner of the plot. Conversely, a test with only a random
relationship to the outcome—such as the toss of a coin—
would be a straight line at a 45° angle from the lower left
to upper right. For two tests of less-than-perfect accu-
racy, the one whose ROC curve is closer to the idealized
L-shaped plot is the more accurate.
The linear combinations of factors derived in the logistic
regression model generate a risk score that is converted into
a probability of a positive SLN by using the equation P 
exp(RS)/[1  exp(RS)], where P is the probability of SLN
positivity and RS stands for risk score and is a linear
combination of the chosen covariates.
A decision rule is constructed to categorize the pa-
tient’s SLN as predicted to be positive if the probability
is greater than a given cutoff and is predicted to be
negative otherwise. For each possible cutoff value, the
sensitivity of the rule is the fraction of correct calls
among the true positives, and the specificity is the frac-
tion of correct calls among the true negatives. As the
cutoff is varied, the sensitivity and specificity change and
are plotted in the ROC curve. Two ROC curves can be
constructed for a given model: one for which all the data
are resubstituted into the equation and the other with
leave-one-out cross-validation. The cross-validated ROC
curve is generally considered the more legitimate esti-
mate and is the one presented.
RESULTS
There were 429 consecutive patients identified in the
database (248 men and 181 women) during the 3.5-year
study. Of these, 419 patients (97.7%) had an identified
and evaluated SLN and available data, and they form the
basis of this report. Thirty-one patients underwent simul-
taneous SLN biopsies from two or three different nodal
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basins (primary lesion location with more than one pri-
mary nodal basin, such as the trunk), and these patients
were considered positive if at least one biopsy in one or
more basins identified a positive SLN. There were 416
patients for whom the site of the primary melanoma was
available. These broke down in the following manner: 58
were located on the head or neck, 187 were located on
the trunk, 69 were located on an upper extremity, and
102 were located on a lower extremity. One or more
histologically or immunohistochemically positive lymph
nodes were found in 76 (18.1%) of 419 patients.
Table 1 consists of descriptive statistics for each of the
histological and clinical factors considered, including a
breakdown of the SLN biopsy results for the patients
who had each factor. The unadjusted percentage of pos-
itive SLN biopsies was slightly higher for men than
women and for primary tumors of the trunk and lower
extremity. The percentage of positive biopsies increased
with increasing tumor thickness and with increases in the
number of mitoses per square millimeter (mitotic rate).
The percentage of positive SLN biopsies was higher for
those primary tumors with any adverse histological fea-
tures except regression. Patients ranged in age from 9 to
80 years old and were arbitrarily divided into three age
groups: 35, 35 to 60, and 60 years of age. It is
interesting to note that the percentage of node-positive
biopsies was highest for the youngest age group (35
years; 26.3% positive) and was progressively lower for
the older groups (35 to 60 years, 18.6% positive; 60
years, 11.8% positive).
Table 2 summarizes the results of univariate analyses
of the relationships described previously, for each factor
by itself and when adjusted for age and sex. When
considered alone, the number of mitoses per square mil-
limeter (P  .0001), increasing Breslow depth (P 
.0001), decreasing age (P  .003), presence of ulceration
(P  .04), and having a primary melanoma located on
the trunk (P  .01) or upper extremity (P  .02, inverse
correlation) showed a significant relationship with the
incidence of one or more positive SLNs. Angiolymphatic
spread showed a marginally significant association (P 
.09). In addition, the presence of increasing numbers of
high-risk factors as described by Mraz-Gernhard et al.8
was strongly associated with the incidence of positive
SLNs (P  .0009). When adjusted for age and sex, the
results were nearly identical. The only exception was that
an upper extremity primary tumor site was no longer
associated with a statistically significant decrease in the
probability of a positive node (adjusted P  .06).
Multivariate analysis revealed that once age, number
of mitoses per square millimeter, and Breslow thickness
were included, no other factor was significantly associ-
ated with the incidence of a positive SLN. Forcing the
addition of sex to the multivariate model resulted in
identical results. Thus, the results of multivariate analy-
sis indicate that once age, Breslow thickness, and mitotic
rate are accounted for, no other prognostic feature (in-
cluding ulceration) adds independent predictive value.
Of note, however, if we had not included mitotic rate in
our model, then the odds ratio estimate for ulceration
would be 2.01 (95% confidence interval, 1.14–3.54; P 
.02). With age, ulceration, and mitotic rate, the odds ratio
for ulceration is 1.48 (95% confidence interval, .81–2.70;
P  .21).
Testing for interaction among the predictive variables
indicated a complex relationship between age, thickness,
and mitotic rate and the probability of a positive biopsy.
TABLE 1. Sentinel lymph node (SLN) biopsy results for
each of the histological and clinical factors considered
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There was a significant interaction between Breslow
thickness and mitotic rate (P  .01), Breslow thickness
and age (P  .02), and age and mitotic rate (P  .01) on
the probability of SLN positivity.
The results of the multivariate analysis led to the
construction of a probabilistic model by using the equa-
tion described in Methods. The final model contains
Breslow depth, number of mitoses, age, and all two-way
interactions between them, where the value for the risk
score (RS) in the equation is calculated by the formula:
RS  .8832  .0387 age  1.2042 mitoses
 .2862 Breslow  .0165 age mitosis
 .0131 age Breslow  .0509 mitosis Breslow)
The results of the multivariate analysis can be ex-
pressed graphically by using logistic regression analysis
that displays the predicted probability of a positive SLN
biopsy when two of the three factors are fixed. Figure 1
shows probability plots over the range of each of the
factors included in the final model when the other two
factors are fixed. Thus, for a fixed age and mitotic rate
(Fig. 1A), the predicted probability of a positive biopsy
increases as the Breslow thickness of the tumor in-
creases. At a fixed thickness and age, the predicted
probability increases as the number of mitoses per square
millimeter increases (Fig. 1B). Finally, at a fixed thick-
ness and mitotic rate, the likelihood of a positive biopsy
decreases with increasing age (Fig. 1C).
The effect of this interaction is shown graphically in
Fig. 2, which demonstrates the interaction between age
and tumor thickness when the mitotic rate is held con-
stant. For younger patients (age 35 in this illustration, in
which only four specific ages are shown for clarity of
presentation), the likelihood of a positive biopsy is rel-
atively less dependent on tumor thickness, ranging from
TABLE 2. Univariate analyses of the relationships between the histological and clinical factors considered, for each factor by
itself and when adjusted for age and sex
Factor P value OR 95% CI
Univariate analysis
Angiolymphatic spread .09 2.40 .87–6.63
Regression .73 .88 .43–1.78
Number of mitoses/mm2 .0001 1.26 1.13–1.41
High mitotic rate (5/mm2) .003 3.59 1.52–8.45
Vertical growth phasea .56 .79 .34–1.78
Satellitosis .30 1.88 .57–6.17
Ulceration .04 1.78 1.03–3.09
Neurotropism .23 2.10 .63–7.00
Periadnexal extension present .72 1.52 .16–14.8
Breslow depth .0001 1.31 1.15–1.50
Head and neck location .23 .60 .26–1.38
Trunk location .01 1.92 1.16–3.18
Upper extremity location .02 .32 .12–.82
Lower extremity location .68 1.13 .63–2.01
Sex .52 1.18 .71–1.97
Age .003 .98 .96–.99
High-risk factorsb .0009 1.85 1.28–2.65
Univariate analysis with adjustment for age and sex
Angiolymphatic spread .06 2.67 .94–7.56
Regression .73 .88 .43–1.80
Number of mitoses/mm2 .0001 1.27 .14–1.42
High mitotic rate (5/mm2) .005 3.53 1.47–8.47
Vertical growth phasea .53 .76 .33–1.77
Satellitosis .22 2.18 .63–7.58
Ulceration .02 1.93 1.09–3.43
Neurotropism .11 2.74 .80–9.41
Periadnexal extension present .70 1.58 .16–16.1
Breslow depth .0001 1.32 1.15–1.51
Head and neck location .30 .64 .27–1.50
Trunk location .04 1.72 1.02–2.87
Upper extremity location .06 .39 .15–1.03
Lower extremity location .82 1.07 .59–1.95
High-risk factorsb .0005 1.96 1.34–2.86
OR, odds ratio; CI, confidence interval.
a Subjects with unknown growth phase were not counted as vertical growth phase.
b High-risk factors were ulceration, microsatellites, angiolymphatic invasion, and high mitotic rate (more than five mitoses per square millimeter).
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a predicted probability of just under 20% for a 1-mm
tumor that has one mitosis per square millimeter to
slightly below 30% for a 6-mm tumor with the same
mitotic rate. By contrast, for older patients, the likelihood
of a positive biopsy is far more dependent on thickness—
well under a 10% probability for a 65-year-old patient
with a 1-mm tumor and one mitosis per square millime-
ter to approximately 45% for a same-age patient with a
6-mm tumor and the same mitotic rate. Although the num-
ber of patients sampled with tumors 1 mm thick was very
small, the trend in Fig. 2 strongly suggests that patients 35
years old who have tumors thinner than 1 mm may still
have a substantial risk for having a positive SLN.
Figure 3 offers an alternate illustration of the varying
effects of mitotic rate with age. In younger patients (the
probability data for 35 years of age are shown in Fig.
3A), when the mitotic rate is high, there is a high prob-
ability of finding a positive SLN at all tumor thicknesses
from 1 to 7 mm. The relative flatness of the curves,
especially for the highest mitotic rates illustrated, reflects
the relative insensitivity of the probability prediction to
changes in tumor thickness. In contrast, for a 50-year-old
patient (Fig. 3B), the number of mitoses greatly affects
the likelihood of finding a positive node for a fairly thin
tumor but not for a very thick tumor. For a 65-year-old
patient (data not shown), there is almost no effect of the
number of mitoses on the likelihood of finding a positive
node over almost the entire range of tumor thicknesses.
This is nicely shown graphically by observing the de-
creasing effect of mitotic rate on the predicted probabil-
ity of a positive node with increasing age for a 1.5-mm-
thick tumor (Fig. 4).
As previously indicated, the overall accuracy of pre-
dictive models or tests can be displayed and compared by
examining ROC curves. Figure 5 compares four vali-
dated ROC curves by using different predictive formulas.
Breslow thickness alone has poor sensitivity and speci-
ficity—better than a coin flip but not by much. Adding
FIG. 1. Breslow depth, age, and mitotic rate are independent variables on multivariate analysis for predicting the presence of a positive sentinel
lymph node (SLN). To derive a probabilistic model for the occurrence of one or more positive SLNs, a multivariate logistic model was fit by using
a stepwise variable selection method. A probability plot was generated for each independent factor while the other factors were kept constant. (A)
For a fixed age and mitotic rate (50 years old and one mitosis per square millimeter), the predicted probability of a positive SLN increases as the
Breslow thickness of the tumor increases. At a fixed thickness and age (in this case, 1.5 mm and 50 years), the predicted probability increases as the
number of mitoses per square millimeter increases (B). At a fixed thickness and mitotic rate (1.5 mm and one mitosis per square millimeter), the
likelihood of a positive SLN decreases with increasing age (C).
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ulceration to the Breslow thickness (as in the new Amer-
ican Joint Committee on Cancer [AJCC] staging system
for melanoma) actually does little to increase the accu-
racy of prediction; the two curves overlap over virtually
their entire course. In contrast, the ROC curve for the
predictive model of Breslow thickness, age, and mitotic
rate moves modestly up and to the left relative to the first
two curves, indicating slightly greater sensitivity and
specificity. To see whether accuracy could be improved
further by adding more information to the predictive
model, the fourth curve uses the total number of high-
risk factors8—ulceration, high mitotic rate, microsatelli-
tosis, angiolymphatic spread, vertical growth phase, and
regression—but does not improve the shape of the ROC
curve at all. It is worth noting that the large area to the
left and above the highest ROC curve represents the
relatively large domain of predictive information that is
not included in any of the predictive models tested.
DISCUSSION
The SLN biopsy represents one of the most significant
advances in melanoma management over the past de-
cade. It allows for selective application of therapeutic
lymph node dissection only to node-positive patients
with melanoma. As such, it maximizes the likelihood
that a survival benefit will be realized with this ap-
proach.15 However, demonstration of a survival benefit is
not a requisite to justify the use of the procedure. SLN
biopsy is a staging technique that is superior to any
others yet identified. As long as the need for accurate
staging of the regional nodes exists, the procedure is
justified if it can be performed with high success rates,
low false-negative rates, and minimal morbidity.
In our series, 18% of patients who underwent lym-
phatic mapping and SLN biopsy had one or more posi-
tive SLNs, a figure very consistent with other studies.
Numerous studies have reported a number of clinical and
histopathologic factors that correlate with the predictive
probability of the SLN status. Results from these studies
using variable statistical methods have yielded conflict-
ing conclusions. The single uniform factor that correlates
with SLN status is the Breslow thickness of the primary
lesion, although uniform cutoffs for depth categories are
missing from these studies. Collectively, however, as the
Breslow depth increases, the probability of a positive
SLN increases. Evaluating Breslow depth alone, for le-
sions 1.0 mm in thickness, the published collective rate
of SLN positivity is 5%.2,7,8,13,16,18 In lesions 3.0
mm, the published rate of SLN positivity ranges from
20% to 50%.2,7–10,13,16–18,20,21,23
Several reports have studied other primary lesion fac-
tors associated with SLN status. Breslow thickness is
consistently reported in association with SLN status.
FIG. 2. The effect of Breslow
thickness on sentinel lymph node
(SLN) positivity is greater with in-
creasing age. A probability plot for a
positive SLN for increasing age and
Breslow depth at a constant number
of mitoses (one per square milli-
meter) demonstrates that Breslow
depth has a more significant effect
with increasing age (i.e., a steeper
slope to the curves at older ages).
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Microsatellitosis, vascular invasion (including angiolym-
phatic invasion), higher mitotic rate, vertical growth
phase, age 60 years, Clark level greater than III, mul-
tiple nodal basins, axial location, and ulceration have
been reported with conflicting results in association with
a positive SLN in numerous series.2,8,13,14,18–23
With univariate analysis from our patients entered into
a database, the following factors had a significant rela-
FIG. 3. Effect of Breslow thickness
and mitotic rate at age 35 and age 50.
At age 35 (A), the effect of Breslow
thickness on the likelihood of a posi-
tive sentinel lymph node (SLN) is
most significant (i.e., the slope of the
curve is steepest) when the mitotic
rate is 0 (solid line). With increasing
mitotic rate, the likelihood of a posi-
tive SLN increases (i.e., the entire
curve rises), and the effect of depth
on probability decreases (the slope
falls). At a mitotic rate of three per
square millimeter, the curve is nearly
flat: Breslow depth has a minimal
effect on the probability of a positive
SLN, with a similar likelihood for
both a 1-mm melanoma and a 7-mm
melanoma. At age 50 (B), the mitotic
rate demonstrates less effect (less
separation of the curves), and in-
creasing Breslow thickness is the best
predictor of a positive SLN (i.e.,
there is a steep slope for all curves,
with convergence of the curves at
high Breslow thicknesses).
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tionship with a positive SLN: number of mitoses (P 
.0001), presence of ulceration (P  .04), Breslow depth
(P .0001), younger age (P  .003), and upper extrem-
ity (P  .02, inverse correlation) or truncal (P  .01)
location. Multivariate analysis demonstrated that once
age, number of mitoses, and Breslow depth were in-
cluded, no other factor—including ulceration—was sig-
nificantly associated with a positive SLN.
Our results stand in contrast to several other studies
that have reported an association between the presence of
ulceration and a positive SLN status.2,7,8,12,13,19–23 This
difference may be due to differences in the diagnostic
criteria used to define ulceration or to differences in the
end point measured (H&E-positive nodes vs. H&E-
and/or immunochemistry-positive nodes, as in our
study), or they may be due to the number of histological
features studied. The AJCC has defined ulceration
broadly as the absence of an intact epidermis overlying
the melanoma. Interpretation of ulceration, however, var-
ies, even among dermatopathologists who specialize in
melanoma.25 For example, lesions with exuberant scale
crust and serum at the surface and a markedly attenuated
epidermis may, in fact, have a thin rim of stratum cor-
neum or parakeratotic scale at the surface. Some experts
may regard this as a sign of ulceration, whereas others
(including ourselves) do not. By standard convention, in
the presence of ulceration, Breslow depth is obtained by
measuring from the base of the ulcer to the deepest tumor
extension. This potentially results in a thinner Breslow
depth in ulcerated versus nonulcerated lesions, another
factor that may in part explain an association between
ulceration and a worse-than-expected prognosis for a
given Breslow depth. At our institution, two measure-
ments are routinely obtained if a lesion is ulcerated: one
from the base of the ulcer and another in the deepest area
of tumor extension overlying intact epidermis. Final as-
signment of depth is based on the deeper of the two
measurements. This may represent another reason why,
in our multivariate analysis, ulceration is not a significant
factor.
Although variable criteria for the definition of ulcer-
ation may explain some of the differences seen in various
published analyses, another part is the inclusion or ex-
clusion of other factors in the multivariate analysis. Not
all authors, for example, include the number of mitoses
per square millimeter in their multivariate model. With-
out this factor, ulceration would have been considered a
significant variable predicting for SLN positivity in our
series. With age, ulceration, and mitotic rate, the odds
ratio estimate for ulceration is 1.48 (95% confidence
interval, .81–2.70; P  .21). If mitotic rate is removed,
then the odds ratio for ulceration is 2.01 (95% confidence
interval, 1.14–3.54; P  .02). Clearly, given the prom-
inence that ulceration now plays in the revised AJCC
FIG. 4. The effect of mitotic rate
on sentinel lymph node (SLN) posi-
tivity is lost with increasing age. A
probability plot for a positive SLN
for increasing age and mitotic rate for
a 1.5-mm Breslow depth melanoma
demonstrates that mitotic rate loses
its significance in predicting nodal
positivity with increasing age. At 35
years of age or younger, there is
marked separation of the curves for
different mitotic rates, but by age 60,
the various curves have entirely
converged.
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staging system, further study is required to determine the
optimal definition of ulceration, the proper method of
assigning Breslow depth for ulcerated lesions, and the
true independent prognostic significance of ulceration,
particularly when mitotic rate is assessed.
Against this background, our own observations re-
garding the importance of age as a predictor for SLN
positivity bear further elaboration. In melanoma, increas-
ing age is generally thought of as a negative prognostic
factor for survival,15 yet our results showed that decreas-
ing age was associated with an increased likelihood of
finding a positive node. Of course, this observation does
not mean that stage for stage an older patient would fare
better than a younger one. Our results highlight the
important role of mitotic rate in younger patients; for
melanoma patients 35 years of age or younger, increas-
ing mitotic rate has a greater effect on the SLN positivity
rate than increasing Breslow thickness. Extrapolation of
our results also suggests that young patients with thin
tumors (1 mm) but high mitotic rates likely have an
SLN positivity rate great enough to justify routine per-
formance of SLN biopsy. However, only a prospective
trial can determine how high the risk is and whether there
is a thickness cutoff (e.g., .80 mm, as recently pro-
posed)26 or a specific level of mitotic activity below
which the likelihood of finding a positive SLN is too low
to justify use of the procedure. Still, our results indicate
how arbitrary and incomplete the decision-making pro-
cess can be about suitability for SLN biopsy in thin
melanomas, where traditionally only the presence of
ulceration, regression, an involved deep margin, or—in
some centers—Clark level IV or V invasion is used to
select patients with thin melanomas for SLN biopsy. To
our knowledge, no one has yet advocated selecting
younger patients and, particularly, those with mitotically
active thin melanomas for SLN biopsy.
Because many of the histological factors are correlated
with each other, it is not surprising that different studies
find slightly different sets of significant factors. The
question left unanswered by all these studies is whether
clinicopathologic factors can predict nodal positivity
with sufficient accuracy to actually obviate the need to
perform the diagnostic procedure. To evaluate this ques-
tion directly, we analyzed ROC curves of our data set.
The ROC analysis illustrates the sensitivity and specific-
ity of using Breslow depth and other factors to predict
SLN positivity. From the equations given, the predicted
probability of a positive SLN can be calculated. A cutoff
for the predicted probability is chosen, and this leads to
a specificity and sensitivity. By changing the cutoff
point, one can trade off specificity and sensitivity. Ide-
ally, one would like both high specificity and high sen-
FIG. 5. Receiver operator charac-
teristic (ROC) curves for the predic-
tion of sentinel lymph node (SLN)
positivity with different predictive
models. Breslow thickness (curve 1)
alone has the poorest sensitivity and
specificity—little better than a coin
toss. Breslow thickness plus ulcer-
ation (curve 2) does not increase the
accuracy of prediction. The ROC
curve for the predictive model of
Breslow thickness, age, and mitotic
rate (curve 3; solid line) moves up
and to the left relative to the first two
curves, indicating greater sensitivity
and specificity. The fourth curve uses
the total number of high-risk factors
(hrf)—ulceration, high mitotic rate,
microsatellitosis, angiolymphatic
spread, vertical growth phase, and re-
gression—but does not improve the
shape of the ROC curve at all.
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sitivity. The actual values of sensitivity and specificity in
the ROC curves are far from representing an ideal test.
For example, if the multivariate model is used and the
cutoff for predicting that an SLN will be positive is a
prediction score (generated by the multivariate model’s
equation) of .191, the prediction will be wrong for 39%
(sensitivity) of the patients who are truly positive and for
28% (specificity) of the patients who are truly negative.
Although this level of predictive accuracy may be the
best we can currently achieve with the available clinico-
pathologic features, these error rates indicate that there is
still considerable variability in the likelihood of nodal
metastases not accounted for by recognized clinicopath-
ologic factors. The implication of this is clear: until and
unless new predictive factors can be found, we will never
be able to accurately determine who will have a positive
SLN biopsy with sufficient accuracy to eliminate the
need for the procedure.
SUMMARY
Factors identified as independent predictors of a pos-
itive SLN in our analysis were Breslow depth, number of
mitoses per square millimeter, and younger age. Proba-
bilistic models such as ours may ultimately find their
greatest clinical use in identifying which patients with
melanoma are at sufficient risk for lymph node metasta-
sis to justify the risks of the procedure, rather than
eliminating the need for the procedure itself.
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